Aktie 6838 FORMOSA PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Formosa Pharmaceuticals, Inc.

Aktien

6838

TW0006838006

6838

Schlusskurs Taipei Exchange
Andere Börsenplätze
 00:00:00 14.05.2024 		% 5 Tage % 1. Jan.
53,3 TWD 0,00 % Intraday Chart für Formosa Pharmaceuticals, Inc. +0,76 % +6,71 %
09.05. Formosa Pharmaceuticals kündigt Lizenzvereinbarung mit Tabuk Pharmaceuticals für die Vermarktung von Clobetasolpropionat-Augensuspension zur Behandlung von Entzündungen und Schmerzen nach Augenoperationen an CI
07.03. Formosa Pharmaceuticals, Inc. gibt die FDA-Zulassung für den NDA-Antrag eines weltweit innovativen Hormon-Nanosuspensions-Augentropfens bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals
Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
US FDA approves Eyenovia's eye drug, Formosa Pharma says
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Formosa Pharmaceuticals, Inc.(TPEX:6838) added to S&P Global BMI Index
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
Grand Pharmaceutical Group's Eye Drops Show Safety in Phase 2, 3 Trials
Formosa Pharmaceuticals, Inc. Announces Phase III Clinical Study of a Global Innovative Hormone Nanosuspension Eye Drops Successfully Reached Clinical Endpoint
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Formosa Pharmaceuticals, Inc. Enter into A Collaboration Agreement with Eyenovia, Inc. for the Development of Novel Ophthalmic Therapeutics
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 6838 Aktie
  4. Nachrichten Formosa Pharmaceuticals, Inc.
  5. Andere Sprachen